The potential of utrophin modulators for the treatment of Duchenne muscular dystrophy
- 12 February 2018
- journal article
- review article
- Published by Informa UK Limited in Expert Opinion on Orphan Drugs
- Vol. 6 (3), 179-192
- https://doi.org/10.1080/21678707.2018.1438261
Abstract
Introduction: Duchenne muscular dystrophy (DMD) is a lethal, X-linked muscle-wasting disease caused by the lack of dystrophin. A few years after the identification of the dystrophin gene, a ubiquitously expressed transcript with high homology to dystrophin was identified leading to the postulate that utrophin might be an effective surrogate to compensate for the lack of dystrophin in dystrophic muscles. Areas covered: We review the utrophin gene, its regulation, the organisation of the corresponding protein and its dynamic expression pattern in comparison with dystrophin. In view of the evidence that utrophin acts as an efficient substitute to dystrophin to prevent the pathology, we describe the therapeutic approaches to modulate utrophin expression. We review the current status in the development of ezutromid, the first small utrophin modulator drug currently tested in DMD patients. Expert opinion: A utrophin based strategy is a highly promising approach applicable to all DMD patients irrespective of their genetic defect. Whereas accurate utrophin and regeneration quantification tools are urgently needed, the foundation of utrophin based therapies, defined 20 years ago, recently delivered first promising results in DMD patients with ezutromid. The field is at an exciting stage on the road of a universal treatment for all DMD patients.Keywords
Funding Information
- Medical Research Council
- Muscular Dystrophy UK, MDUK
- Duchenne Trust and Summit Therapeutics plc.
This publication has 96 references indexed in Scilit:
- UtroUp is a novel six zinc finger artificial transcription factor that recognises 18 base pairs of the utrophin promoter and efficiently drives utrophin upregulationBMC Molecular Biology, 2013
- TAT-μUtrophin mitigates the pathophysiology of dystrophin and utrophin double-knockout miceJournal of Applied Physiology, 2011
- Daily Treatment with SMTC1100, a Novel Small Molecule Utrophin Upregulator, Dramatically Reduces the Dystrophic Symptoms in the mdx MousePLOS ONE, 2011
- Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx miceProceedings of the National Academy of Sciences, 2010
- Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophinJournal of Cell Science, 2010
- Functional Substitution by TAT-Utrophin in Dystrophin-Deficient MicePLoS Medicine, 2009
- Microutrophin Delivery Through rAAV6 Increases Lifespan and Improves Muscle Function in Dystrophic Dystrophin/Utrophin-deficient MiceMolecular Therapy, 2008
- Heregulin‐induced epigenetic regulation of the utrophin‐A promoterFEBS Letters, 2007
- Postnatal overexpression of the CT GalNAc transferase inhibits muscular dystrophy in mdx mice without altering muscle growth or neuromuscular development: Evidence for a utrophin-independent mechanismNeuromuscular Disorders, 2007
- Pharmacological strategies for muscular dystrophyNature Reviews Drug Discovery, 2003